The addition of acetazolamide to high-dose loop diuretic therapy in patients with volume overload secondary to acute decompensated heart failure (ADHF) results in substantial natriuresis, shorter hospital stays, fewer readmissions, and longer survival, a new analysis from the ADVOR trial suggests.